Posts

Showing posts from June, 2024

Fenbendazole Review by Dr David Gorski: Fenbendazole is fast becoming the laetrile of the 2020s

Image
Let’s start with the article that caught my attention over the weekend,  Triple-Negative Breast Cancer Eradicated by Fenbendazole , in which 2SGitW brags, “Fenbendazole kills the cancer cells responsible for killing cancer patients.” As I learned, it’s a followup to a  cancer cure testimonial published a week earlier  on the Substack in which 2SGitW massively exaggerated the the significance of some promising preclinical and lab studies suggesting that fenbendazole might have anticancer activity against triple-negative breast cancer written by someone going under the ‘nym of  BenFen , who claims to be a “retired University scientist who happened across fenbendazole when a loved one developed terminal cancer” and runs a  Substack  that publishes cancer cure testimonials due to fenbendazole. More interestingly, it turns out that fenbendazole repurposing has been a favorite “alternative cancer cure” since at least 2017, if not earlier, but the rise of ivermectin and other dewormers as “cu

Repurposed Drugs for Cancer: What You Need to Know (2024)

Image
A rapidly growing subcategory in the chemotherapeutic treatment of cancer is the utilization of prescription drugs originally approved for treating conditions other than cancer. Such off-label use of drugs has taken the world of integrative oncology by storm. This strategy has potential for increasing efficacy of treatment. At the same time, it raises deep questions on how we define naturopathic medicine, natural medicine, and our role as physicians. Will using pharmaceutical drugs to prolong a patient’s life fit into who we claim to be as naturopathic physicians? One of the earliest non-cancer drugs noted to have anticancer side effect was cimetidine. Cimetidine was an early H-2 agonist approved for treating gastric ulcers in the late 1970s. Reports of an anticancer effect appeared not long afterward; the earliest was likely Armitage and Sidner’s 1979 paper,1 but Burtin’s 1988 trial usually receives the credit. Burtin reported that cimetidine or ranitidine combined with subcutan

Labels

Show more

Archive

Show more